Moon Kyle J, Linton Sabriya L, Kazerouni Neda J, Levander Ximena A, Irwin Adriane N, Hartung Daniel M
Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, 624 N Broadway, Baltimore, MD 21205, USA.
Boise VA Medical Center, 500 W Fort Street, Boise, ID 83702, USA.
Drug Alcohol Depend Rep. 2024 Jul 14;12:100255. doi: 10.1016/j.dadr.2024.100255. eCollection 2024 Sep.
Timely and reliable dispensing of buprenorphine is critical to accessing treatment for opioid use disorder (OUD). Racial and ethnic inequities in OUD treatment access are well described, but it remains unclear if inequities persist at the point of dispensing.
We analyzed data from a U.S. telephone audit that measured restricted buprenorphine dispensing in community pharmacies, defined as inability to fill a buprenorphine prescription requested by a "secret shopper." Using the Index of Concentration at the Extremes (ICE), we constructed county-level measures of racial, ethnic, economic, and racialized economic (joint racial and economic segregation) segregation. Logistic regression models evaluated the association of ICE measures and restricted buprenorphine dispensing, adjusting for county type (urban vs. rural) and pharmacy type (chain vs. independent).
Among 858 pharmacies surveyed in 473 counties, pharmacies in the most ethnically segregated and economically deprived counties had 2.66 times the odds (95 % CI: 1.41, 5.17) of restricting buprenorphine dispensing, compared to pharmacies in the most privileged counties after adjustment. Pharmacies in counties with high racialized economic segregation (quintile 2 and 3) also had higher odds of restricting buprenorphine dispensing (aOR 3.09 [95 % CI 1.7, 5.59]; aOR 2.11 [95 % CI 1.17, 3.98]). Similar associations were observed for economic segregation (aOR: 2.18 [95 % CI: 1.21, 3.99]), but not ethnic (0.59 [0.34, 1.05]) or racial (0.61 [0.35, 1.07]) segregation alone.
Restricted buprenorphine dispensing was most pronounced in socially and economically disadvantaged communities, potentially exacerbating gaps in OUD treatment access. Policy interventions should target both prescribing and dispensing capacity to advance pharmacoequity.
及时且可靠地发放丁丙诺啡对于获得阿片类物质使用障碍(OUD)治疗至关重要。OUD治疗可及性方面的种族和民族不平等现象已有详尽描述,但在发放环节不平等现象是否依然存在尚不清楚。
我们分析了一项美国电话审计的数据,该审计衡量社区药房中受限的丁丙诺啡发放情况,定义为无法配给“暗访者”所要求的丁丙诺啡处方。使用极端集中度指数(ICE),我们构建了县级种族、民族、经济以及种族化经济(种族与经济联合隔离)隔离的衡量指标。逻辑回归模型评估了ICE指标与受限丁丙诺啡发放之间的关联,并对县类型(城市与农村)和药房类型(连锁与独立)进行了调整。
在473个县的858家接受调查的药房中,经调整后,与最具优势的县的药房相比,种族隔离最严重且经济最贫困县的药房限制丁丙诺啡发放的几率高2.66倍(95%置信区间:1.41,5.17)。种族化经济隔离程度高(第二和第三五分位数)县的药房限制丁丙诺啡发放的几率也更高(调整后比值比3.09 [95%置信区间1.7,5.59];调整后比值比2.11 [95%置信区间1.17,3.98])。经济隔离也观察到类似关联(调整后比值比:2.18 [95%置信区间:1.21,3.99]),但单独的民族隔离(0.59 [0.34,1.05])或种族隔离(0.61 [0.35,1.07])则未观察到。
受限的丁丙诺啡发放情况在社会和经济弱势社区最为明显,这可能加剧了OUD治疗可及性方面的差距。政策干预应针对处方开具和发放能力,以促进药物公平。